Commission on Cancer CP3R Compliance Rates for Treatment of Patients With Triple Negative and HER2+ Breast Cancer: A National Cancer Database Analysis.
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Biomarkers, Tumor
Breast Neoplasms
/ drug therapy
Chemotherapy, Adjuvant
Databases, Factual
Female
Humans
Immunotherapy
Medication Adherence
Middle Aged
Neoplasm Staging
Quality of Health Care
Receptor, ErbB-2
Triple Negative Breast Neoplasms
/ drug therapy
United States
Cancer Program Practice Profile Report
National Cancer Database
breast cancer
Journal
The American surgeon
ISSN: 1555-9823
Titre abrégé: Am Surg
Pays: United States
ID NLM: 0370522
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
pubmed:
22
10
2021
medline:
15
12
2021
entrez:
21
10
2021
Statut:
ppublish
Résumé
Cancer Program Practice Profile Reports (CP3R) metrics were released by the Commission on Cancer to provide standards for high-quality care. One metric is the recommendation of combination chemotherapy or chemo-immunotherapy (CIT) within 120 days of diagnosis for women under 70 with AJCC T1cN0M0 or Stage IB-III HER2+ or hormone receptor negative breast cancer ([Multi-agent chemotherapy] MAC). Our study assesses national concordance rates for MAC and CIT. The National Cancer Database was queried from 2004-2014. 122,045 patients met criteria, of whom treatment for 101,800 (83.4%) patients was concordant with MAC and CIT. Treatment concordance increased from 75.7% in 2004 to 89.5% in 2014. For HER2+ patients, use of CIT treatment downtrended with progression of pathological stage, from 70.1% (stage I) to 58.1% (stage III). Mean overall survival of patients whose treatment was concordant with MAC and CIT was longer than that of patients who were non-concordant (146.6 vs 143.8 months, Compliance with MAC and CIT has improved over the past decade and is associated with a significant improvement in overall survival.
Sections du résumé
BACKGROUND
BACKGROUND
Cancer Program Practice Profile Reports (CP3R) metrics were released by the Commission on Cancer to provide standards for high-quality care. One metric is the recommendation of combination chemotherapy or chemo-immunotherapy (CIT) within 120 days of diagnosis for women under 70 with AJCC T1cN0M0 or Stage IB-III HER2+ or hormone receptor negative breast cancer ([Multi-agent chemotherapy] MAC). Our study assesses national concordance rates for MAC and CIT.
METHODS
METHODS
The National Cancer Database was queried from 2004-2014.
RESULTS
RESULTS
122,045 patients met criteria, of whom treatment for 101,800 (83.4%) patients was concordant with MAC and CIT. Treatment concordance increased from 75.7% in 2004 to 89.5% in 2014. For HER2+ patients, use of CIT treatment downtrended with progression of pathological stage, from 70.1% (stage I) to 58.1% (stage III). Mean overall survival of patients whose treatment was concordant with MAC and CIT was longer than that of patients who were non-concordant (146.6 vs 143.8 months,
CONCLUSION
CONCLUSIONS
Compliance with MAC and CIT has improved over the past decade and is associated with a significant improvement in overall survival.
Identifiants
pubmed: 34672825
doi: 10.1177/00031348211051674
doi:
Substances chimiques
Biomarkers, Tumor
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM